Your browser is no longer supported. Please, upgrade your browser.
ALIM [NASD]
Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own1.80% Shs Outstand5.07M Perf Week13.79%
Market Cap29.24M Forward P/E- EPS next Y-0.30 Insider Trans-1.46% Shs Float4.29M Perf Month56.03%
Income-3.90M PEG- EPS next Q-0.10 Inst Own40.30% Short Float0.39% Perf Quarter42.32%
Sales54.40M P/S0.54 EPS this Y-159.00% Inst Trans- Short Ratio0.27 Perf Half Y13.21%
Book/sh-7.17 P/B- EPS next Y71.70% ROA-7.80% Target Price- Perf Year-5.04%
Cash/sh2.55 P/C2.59 EPS next 5Y- ROE10.70% 52W Range2.86 - 8.49 Perf YTD56.40%
Dividend- P/FCF- EPS past 5Y-19.30% ROI-124.80% 52W High-22.29% Beta1.78
Dividend %- Quick Ratio2.90 Sales past 5Y45.00% Gross Margin86.70% 52W Low130.75% ATR0.41
Employees122 Current Ratio3.20 Sales Q/Q-3.10% Oper. Margin1.20% RSI (14)80.06 Volatility9.62% 7.18%
OptionableNo Debt/Eq- EPS Q/Q81.60% Profit Margin-7.10% Rel Volume1.94 Prev Close5.87
ShortableYes LT Debt/Eq- EarningsOct 28 AMC Payout- Avg Volume61.86K Price6.60
Recom2.00 SMA2038.48% SMA5044.06% SMA20026.98% Volume119,798 Change12.44%
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Jan-05-21 08:00AM  
Dec-24-20 09:14AM  
Dec-22-20 10:22AM  
Dec-21-20 10:13AM  
08:45AM  
Dec-17-20 08:42AM  
Dec-16-20 01:31PM  
Dec-15-20 09:57AM  
Dec-14-20 12:59PM  
Dec-11-20 08:34AM  
Dec-10-20 09:40AM  
Dec-09-20 08:33AM  
08:30AM  
Dec-08-20 08:56AM  
08:30AM  
Dec-07-20 09:27AM  
09:27AM  
Dec-04-20 08:45AM  
Dec-03-20 10:04AM  
Dec-02-20 07:42PM  
06:03PM  
03:52PM  
Dec-01-20 10:06AM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
Nov-20-20 10:08AM  
Nov-18-20 11:24AM  
Nov-16-20 08:00AM  
Nov-13-20 11:22AM  
Nov-12-20 08:00AM  
Nov-09-20 10:18AM  
Nov-06-20 10:57AM  
10:54AM  
10:52AM  
Nov-05-20 11:38AM  
Nov-04-20 12:00PM  
Oct-30-20 02:31PM  
06:15AM  
Oct-29-20 07:00AM  
Oct-28-20 06:25PM  
04:05PM  
Oct-22-20 08:00AM  
Sep-23-20 08:00AM  
Sep-15-20 08:00AM  
Sep-09-20 11:18AM  
08:00AM  
Sep-08-20 08:00AM  
Sep-01-20 10:10AM  
08:00AM  
Aug-31-20 05:00PM  
Aug-30-20 09:47AM  
Aug-26-20 08:30AM  
Aug-25-20 08:00AM  
Aug-13-20 08:00AM  
Aug-05-20 12:00PM  
11:44AM  
09:00AM  
Jul-31-20 12:30PM  
Jul-29-20 06:25PM  
05:32PM  
04:05PM  
Jul-23-20 11:15AM  
Jul-22-20 08:00AM  
Jul-09-20 08:00AM  
Jun-25-20 10:37AM  
Jun-23-20 06:36PM  
Jun-16-20 10:25AM  
Jun-10-20 06:04PM  
Jun-03-20 09:00AM  
08:00AM  
Apr-30-20 08:30PM  
Apr-29-20 06:25PM  
04:00PM  
Apr-24-20 08:00AM  
Apr-23-20 08:00AM  
Apr-13-20 08:36AM  
Mar-31-20 12:43PM  
08:00AM  
Mar-26-20 08:18AM  
Mar-25-20 08:00AM  
Feb-29-20 07:32AM  
Feb-26-20 06:35PM  
04:05PM  
Feb-24-20 08:00AM  
Feb-20-20 08:00AM  
Jan-29-20 04:52AM  
Jan-27-20 08:11AM  
Jan-10-20 04:11PM  
Jan-06-20 08:00AM  
Dec-17-19 07:20PM  
Dec-11-19 12:01PM  
Dec-04-19 08:30AM  
Dec-03-19 08:30AM  
Nov-26-19 08:30AM  
Nov-20-19 03:32AM  
Nov-14-19 12:45PM  
Nov-13-19 08:00AM  
Nov-08-19 08:14AM  
Nov-07-19 06:00PM  
Nov-05-19 08:30AM  
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ashman PhilipChief Operating Officer & SVPNov 04Buy4.501,3165,92211,957Nov 05 02:46 PM
EISWIRTH RICHARD S JRPresident and CEONov 02Buy4.152,50010,37742,043Nov 04 04:53 PM
Myers C. DanielDirectorAug 20Sale6.735,00033,6505,578Aug 24 04:25 PM